東方生物(688298.SH)上市首日大漲586.96%提示風險 於近日完成新型冠狀病毒系列檢測試劑新品的研發
格隆匯2月5日丨東方生物(688298.SH)公佈,公司股票上市首日漲幅達到586.96%,對應公司2018年扣除非經常性損益前後孰低的攤薄後市盈率為280倍,公司所處的醫藥製造業最近一個月平均滾動市盈率為35.33倍,顯著高於行業市盈率水平。
公司於近日完成了新型冠狀病毒(2019-nCoV)系列檢測試劑新品的研發。該系列產品包括基於膠體金免疫層析法的2019-nCoV新型冠狀病毒抗原快速檢測試紙,以及基於熒光PCR平台的2019-nCoV新型冠狀病毒核酸檢測試劑盒。相關產品已經完成了初步臨牀試驗工作,公司正組織新型冠狀病毒相關檢測試劑的註冊申報工作,目前處於資料準備和提交階段。
截至目前公司已向浙一醫院、樹蘭醫院和疾控中心捐贈價值十多萬元的設備與核酸即時診斷試劑盒。
上述產品不會對公司當期收入及利潤產生影響。未來的銷售情況取決於此次疫情防控情況的發展,對未來業績是否帶來有利影響還存在重大的不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.